Microsphere-based antibody assays for human parvovirus B19V, CMV and T. gondii

Wang, Yilin; Hedman, Lea; Perdomo, Maria F.; Elfaitouri, Amal; Bölin-Wiener, Agnes; Kumar, Arun; Lappalainen, Maija; Söderlund‐Venermo, Maria; Blomberg, Jonas; Hedman, Klaus

doi:10.1186/s12879-015-1194-3

Cited by 16 publications

(19 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both in a high-positive adult (Case 1) and in a low-positive adult (Case 5), we could show that the BuV antibody levels and specificity remained constant for at least six years (Table 2). Furthermore, among the 84 medical students, the BuV1-3 and TuV IgG EIA results correlated neither with each other nor with the previously analysed IgG EIA results of six other human parvoviruses: HBoV1-4, PARV4, or parvovirus B19 (data not shown)192021.…”

Section: Resultsmentioning

confidence: 59%

Epidemiology of two human protoparvoviruses, bufavirus and tusavirus

Väisänen

Paloniemi

Kuisma

et al. 2016

Sci Rep

Self Cite

View full text Add to dashboard Cite

Two human parvoviruses were recently discovered by metagenomics in Africa, bufavirus (BuV) in 2012 and tusavirus (TuV) in 2014. These viruses have been studied exclusively by PCR in stool and detected only in patients with diarrhoea, although at low prevalence. Three genotypes of BuV have been identified. We detected, by in-house EIA, BuV1-3 IgG antibodies in 7/228 children (3.1%) and 10/180 adults (5.6%), whereas TuV IgG was found in one child (0.4%). All children and 91% of the adults were Finnish, yet interestingly 3/6 adults of Indian origin were BuV-IgG positive. By competition EIA, no cross-reactivity between the BuVs was detected, indicating that the BuV genotypes represent distinct serotypes. Furthermore, we analysed by BuV qPCR stool and nasal swab samples from 955 children with gastroenteritis, respiratory illness, or both, and found BuV DNA in three stools (0.3%) and for the first time in a nasal swab (0.1%). This is the first study documenting the presence of BuV and TuV antibodies in humans. Although the seroprevalences of both viruses were low in Finland, our results indicate that BuV infections might be widespread in Asia. The BuV-specific humoral immune responses appeared to be strong and long-lasting, pointing to systemic infection in humans.

show abstract

Section: Resultsmentioning

confidence: 59%

Epidemiology of two human protoparvoviruses, bufavirus and tusavirus

Väisänen

Paloniemi

Kuisma

et al. 2016

Sci Rep

Self Cite

View full text Add to dashboard Cite

show abstract

“…In such combinatory or "reflex" diagnostics, a feasible strategy is initial screening for antimicrobial IgG and IgM, in a multiplex format, followed by retesting of the IgM-positive samples with a conceptually different test, in singleplex, to attest the infection status. We have previously established microspherebased IgG assays for B19, HCMV, and T. gondii infections (18). In this study, for these important pathogens, we successfully developed (i) IgM SIAs, for use as a primary approach (including screening), as well as (ii) the corresponding IgG avidity SIAs, for assessment of IgM-positive samples.…”

Section: Discussionmentioning

confidence: 99%

“…Panel 2 included 391 serum samples from 140 patients with primary or secondary infections by HCMV, T. gondii, or B19. These patients and specimens have previously been examined serologically for HCMV (35,41), T. gondii (19,42), or B19 (18,24,25,40).…”

Section: Study Samples and Patients (I) Panel 1 Panel 1 Included 23mentioning

confidence: 99%

Microsphere-Based IgM and IgG Avidity Assays for Human Parvovirus B19, Human Cytomegalovirus, and Toxoplasma gondii

Wang

Hedman

Nurmi

et al. 2020

mSphere

Self Cite

View full text Add to dashboard Cite

Human parvovirus B19 (here B19), human cytomegalovirus (HCMV), and Toxoplasma gondii infections during pregnancy can lead to severe complications. While traditional diagnosis of infections is mostly confined to one pathogen at a time, a multiplex array is a feasible alternative to improve diagnostic management and cost-efficiency. In the present study, for these three pathogens, we developed microsphere-based suspension immunoassays (SIAs) in multiplex and monoplex formats for the detection of antimicrobial IgM antibodies as well as corresponding chaotrope-based IgG avidity SIAs. We determined the diagnostic performances of the SIAs versus in-house and commercial reference assays using a panel of 318 serum samples from well-characterized clinical cohorts. All the newly developed assays exhibited excellent performance compared to the corresponding high-quality reference methods. The positive and negative percent agreements of the IgM SIAs in comparison with reference methods were 95 to 100% and 98 to 100%, and those of the IgG avidity SIAs were 92 to 100% and 95 to 100%, respectively. Kappa efficiency values between the SIAs and the corresponding reference assays were 0.91 to 1. Furthermore, with another panel comprising 391 clinical samples from individuals with primary infection by B19, HCMV, or T. gondii, the IgM SIAs were highly sensitive for the detection of acute infections, and the IgG avidity SIAs were highly specific for the separation of primary infections from past immunity. Altogether, the strategy of IgM multiplex screening followed by IgG avidity reflex testing can provide high-throughput and accurate means for the detection and stage determination of B19, HCMV, and T. gondii infections. IMPORTANCE Human parvovirus B19, human cytomegalovirus, and Toxoplasma gondii are ubiquitous pathogens. Their infections are often asymptomatic or mild in the general population yet may be transmitted from mother to fetus during pregnancy. Maternal infections by these pathogens can cause severe complications to the fetus or congenital abnormalities. As a rule, the risk of maternal transmission is critically related to the infection time; hence, it is important to determine when a pregnant woman has acquired the infection. In this study, we developed new diagnostic approaches for the timing of infections by three pathogens. All the new assays appeared to be highly sensitive and specific, providing powerful tools for medical diagnosis.

show abstract

“…Of limited availability and not widely used, although potentially useful to determine the timing with respect to onset of infection, are assays to determine IgG avidity [93], or acute-phase, epitope specific reactivity [94]. Recent technical developments aimed at the setup of The clinical use of Parvovirus Assays, p.14 homogenous phase, multiplexed assays, first proposed the use of array-in-well IgG antibody detection, coupled to photon emitting nanoparticles and photoluminescence reporter technology [95], then a Luminex-based assay for the detection of specific IgG, potentially combined in a multiplex assay aimed at antenatal screening [96].…”

Section: Antibody Detection Assaysmentioning

confidence: 99%

The clinical use of parvovirus B19 assays: recent advances

Gallinella

2018

Expert Review of Molecular Diagnostics

View full text Add to dashboard Cite

Parvovirus B19 (B19V), a single-stranded DNA virus in the family Parvoviridae, is a human pathogenic virus, characterized by a selective but not exclusive tropism for erythroid progenitor cells. Widely diffuse, it is responsible for an ample range of clinical manifestations, whose characteristics and outcomes depend on the interplay between the viral properties and the physiological and immune status of the infected individuals. The complexity of virus-host relationship and the diversity of the clinical course of infection pose a diagnostic challenge that may require non-trivial solutions. Areas covered: The review includes an updated description of the course of B19V infection in its complexity and diversity of pathogenetic mechanisms, discusses the consequent requirements for different and appropriated diagnostic approaches, presents the main diagnostic techniques, more recent technical advancements, and their application to the diverse clinical situations. Expert commentary: The complex scenario of the infectious process and the diversity in possible pathogenetic mechanisms make necessary a multi-parametric approach for an accurate and informative laboratory diagnosis of B19V infection, combining as much as possible the molecular detection of viral components, mainly viral DNA, to commonly followed immunological detection of virus-specific antibodies and a critical assessment of laboratory findings.

show abstract

Microsphere-based antibody assays for human parvovirus B19V, CMV and T. gondii

Cited by 16 publications

References 15 publications

Epidemiology of two human protoparvoviruses, bufavirus and tusavirus

Epidemiology of two human protoparvoviruses, bufavirus and tusavirus

Microsphere-Based IgM and IgG Avidity Assays for Human Parvovirus B19, Human Cytomegalovirus, and Toxoplasma gondii

The clinical use of parvovirus B19 assays: recent advances

Contact Info

Product

Resources

About